[Clinical study on patients with advanced gastric cancer treated with oxaliplatin combining with hydroxycamptothecine].
OBJECTIVE
Internal and external physiological research showed oxaliplatin could obviously suppress several kinds of tumors in combination with most anti-cancer drugs and help these drugs to kill the tumor cells. This study was designed to investigate the initial curative effects and tolerance of patients with advanced gastric cancer of treatment with combination of oxaliplatin (L-OHP) and hydroxycamptothecine (HCPT). We compared this treatment with traditional chemotherapy.


METHODS
In a non-randomized manner, 43 patients with advanced gastric cancer were divided into treatment group (L-OHP plus HCPT) and control group (VP-16 + CF + 5-FU) (ELF). Among these patients, 28 were male and 15 were female. The median age was 59. Karnofsky performance status(KPS) scale was more than 60. We compared the initial curative effects and tolerance between these two groups.


RESULTS
The beneficial effects for the treatment group (24 cases) and control group (19 cases) were 58.3% (14/24) and 42.1% (8/19), respectively. Obviously, the beneficial effects to the treatment group were higher than that of the control group (P < 0.05). The side effects of both groups included bone marrow suppression, nausea, vomiting, stomatitis, neuritis, phlebitis, hair loss, and so on. But they were slight (within I and II degree).


CONCLUSIONS
The use of L-OHP plus HCPT appears to be a very good treatment for patients with advanced gastric cancer. The patients can tolerate the side effects.
Yang
Chun-xu
CX
Department of Oncology, Fourth Affiliated Hospital, Guangxi Medical University, Liuzhou 545005, P. R. China. yangchunxu@163.net
Huang
Hai-xing
HX
Li
Gui-sheng
GS
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; C028098:10-hydroxycamptothecin; D002166:Camptothecin